Article

Prostate brachytherapy use on the rise in United States

The percentage of American men with early prostate cancer who were treated with brachytherapy increased from less than 5% in 1994 to 36% in 1999, according to a report published in Cancer (2003; 98: 1987-94).

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Urology Times Mitomycin RX Review Square Thumb
RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practice
Urology Times Mitomycin RX Review Square Thumb
RX Review: TURBT vs chemoablation for low-grade, intermediate-risk NMIBC
Urology Times Mitomycin RX Review Square Thumb
RX Review: A paradigm shift for low-grade, intermediate-risk NMIBC
Urology Times Mitomycin RX Review Square Thumb
RX Review: How mitomycin for intravesical solution works in treating LG-IR-NMIBC
Urology Times Mitomycin RX Review Square Thumb
RX Review: Redefining treatment for LG-IR-NMIBC
Vignesh Packiam, MD, on the MOA, dosing of detalimogene voraplasmid
Vignesh Packiam, MD, on the MOA, dosing of detalimogene voraplasmid
Stethoscope and doctor sitting with laptop stress headache about work in hospital | Image Credit: © joyfotoliakid - stock.adobe.com
Understanding pediatric urologist burnout
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Urologist finds Rezum AE rates in larger prostates “reassuring”
Men’s Health Awareness Month: A new era of patient engagement
Men’s Health Awareness Month: A new era of patient engagement
2 experts are featured in this series.
The Logistical Challenges in ccRCC Treatment
Related Content
Enrollment begins in phase 2 trial of opaganib plus darolutamide in mCRPC
July 2nd 2025

Enrollment begins in phase 2 trial of opaganib plus darolutamide in mCRPC

Hannah Clarke
The study will utilize the companion lipid biomarker test, PCPro, to identify patients who may benefit from the addition of opaganib to darolutamide.
Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD
June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD
Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.
Gedatolisib plus darolutamide shows encouraging activity in mCRPC
July 1st 2025

Gedatolisib plus darolutamide shows encouraging activity in mCRPC

Hannah Clarke
The combination demonstrated a 6-month radiographic progression-free survival of 66%.
Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD
June 19th 2025

Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD

Amy M. Pearlman, MD
The conversation covers practical, case-based strategies for counseling MSM patients.
FDA grants breakthrough device designation to urine test for bladder cancer detection
June 30th 2025

FDA grants breakthrough device designation to urine test for bladder cancer detection

Hannah Clarke
The TOBY test works by analyzing the molecular signatures of volatile organic compounds in urine.
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
June 30th 2025

Phase 2 trial of TYRA-300 launches in LG-IR-NMIBC

Hannah Clarke
The primary end point for the trial is the complete response rate at 3 months.
© 2025 MJH Life Sciences

All rights reserved.